TNFRSF4 and melanoma: A key example of this functional conversion was reported in a preclinical melanoma model by Hirschhorn et al., who utilized an aggressive triple-combination therapy consisting of cyclophosphamide preconditioning, adoptive transfer of Trp1-specific CD4+ T cells, and anti-OX40 co-stimulation [17].